Abstract:Limited success has been achieved in ferroptosis-induced cancer treatment due to the challenges related to low production of toxic reactive oxygen species (ROS) and inherent ROS resistance in cancer cells. To address this issue, a self-assembled nanodrug have been investigated that enhances ferroptosis therapy by increasing ROS production and reducing ROS inhibition. The nanodrug is constructed by allowing doxorubicin (DOX) to interact with Fe 2+ through coordination interactions, forming a stable DOX-Fe 2+ chelate, and this chelate further interacts with sorafenib (SRF), resulting in a stable and uniform nanoparticle. In tumor cells, overexpressed glutathione (GSH) triggers the disassembly of nanodrug, thereby activating the drug release. Interestingly, the released DOX not only activates nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) to produce abundant H 2 O 2 production for enhanced ROS production, but also acts as a chemotherapeutics agent, synergizing with ferroptosis. To enhance tumor selectivity and improve the blood clearance, the nanodrug is coated with a related cancer cell membrane, which enhances the selective inhibition of tumor growth and metastasis in a B16F10 mice model. Our findings provide valuable insights into the rational design of self-assembled nanodrug for enhanced ferroptosis therapy in cancer treatment. Statement of significance Ferroptosis is a non-apoptotic form of cell death induced by the iron-regulated lipid peroxides (LPOs), offering a promising potential for effective and safe anti-cancer treatment. However, two significant challenges hinder its clinical application: 1) The easily oxidized nature of Fe2+ and the low concentration of H 2 O 2 leads to a low efficiency of intracellular Fenton reaction, resulting in poor therapeutic efficacy; 2) The instinctive ROS resistance of cancer cells induce drug resistance. Therefore, we developed a simple and high-efficiency nanodrug composed of self-assembling by Fe 2+ sources, H 2 O 2 inducer and ROS resistance inhibitors. This nanodrug can effectively deliver the Fe 2+ sources into tumor tissue, enhance intracellular concentration of H2O2, and reduce ROS resistance, achieving a high-efficiency, precise and safe ferroptosis therapy.

Precise Carrier-Free Pt(IV)-Nanobombs for Apoptosis/Ferroptosis Synergistic Tumor Therapy: A New Effective Method to Obtain Good Chemotherapy and Low Toxicity

A Nanomedicine Based on Stoichiometric Coordination of Camptothecin and Organoplatinum (II) for Synergistic Antitumor Therapy.

Acid-responsive drug-loaded copper phosphate nanoparticles for tumor cell therapy through synergistic apoptosis and ferroptosis strategy

Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy

Multifunctional Platinum Doped Porous FeS 2 Nanoparticles for Photothermal Enhanced Photodynamic Ferroptosis Combination Therapy

Folate-modified, Indocyanine Green-Loaded Lipid-Polymer Hybrid Nanoparticles for Targeted Delivery of Cisplatin

Self-Assembled Metal-Phenolic Network Nanoparticles Delivery of Cisplatin Prodrug for Synergistic Chemo-Immunotherapy

A Dual Stimuli‐responsive Nanoplatform Loaded PtIV‐triptolide Prodrug for Achieving Synergistic Therapy Toward Breast Cancer

A carrier-free anti-inflammatory platinum (II) self-delivered nanoprodrug for enhanced breast cancer therapy

Combination Therapy to Overcome Ferroptosis Resistance by Biomimetic Self-Assembly Nano-Prodrug

Asymmetric silicon phthalocyanine based nanoparticle with spatiotemporally targeting of mitochondria for synergistic apoptosis-ferroptosis antitumor treatment

A Ph Responsive Nanocomposite for Combination Sonodynamic‐immunotherapy with Ferroptosis and Calcium Ion Overload Via SLC7A11/ACSL4/LPCAT3 Pathway

A Glutathione-Responsive Polyphenol - Constructed Nanodevice for Double Roles in Apoptosis and Ferroptosis

Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis Via Triggered GPX4 Inhibition and Concurrent in Situ Bleomycin Toxification.

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

A Supramolecular Self-Assembled Nanoprodrug for Enhanced Ferroptosis Therapy

Targeting ferroptosis synergistically sensitizes apoptotic sonodynamic anti-tumor nanotherapy

Boosting chemotherapy of bladder cancer cells by ferroptosis using intelligent magnetic targeting nanoparticles

Pulmonary Delivery of Theranostic Nanoclusters for Lung Cancer Ferroptosis with Enhanced Chemodynamic/Radiation Synergistic Therapy

Biodegradable Nanoscale Coordination Polymers for Targeted Tumor Combination Therapy with Oxidative Stress Amplification

A homologous membrane-camouflaged self-assembled nanodrug for synergistic antitumor therapy